News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Sirtris Pharmaceuticals Announces FDA Grants Orphan Status for Red-Wine Compound
April 2, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
April 2 (Reuters) - Sirtris Pharmaceuticals Inc said the U.S. health regulators granted orphan drug status for resveratrol, a compound derived from red wine, to treat a fatal muscular disorder.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Diabetes
Lilly Tops Novo in Weight Loss Again, This Time on the Oral Front
February 26, 2026
·
2 min read
·
Annalee Armstrong
HIV
Gilead, Merck Clear Path to Market for Daily HIV Pills With New Late-Stage Data
February 26, 2026
·
2 min read
·
Tristan Manalac
Regulatory
Patient Death Forces Partial Freeze on MacroGenics’ Gynecologic Cancer Study
February 25, 2026
·
2 min read
·
Tristan Manalac
Podcast
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
February 25, 2026
·
2 min read
·
Heather McKenzie